HBV Program
Chronic Hepatitis B Virus Infection (Functional Cure)
Phase 2Active
Key Facts
Indication
Chronic Hepatitis B Virus Infection (Functional Cure)
Phase
Phase 2
Status
Active
Company
About AusperBio
AusperBio is a private, pre-revenue biotech founded in 2019, advancing a novel Antisense Oligonucleotide (ASO) platform called Med-Oligo™. The company's lead program is in Phase II trials for HBV, targeting a functional cure, a significant unmet medical need. By combining its platform with targeted delivery technologies, AusperBio aims to expand into other therapeutic areas beyond virology. Its success hinges on clinical validation of its platform and its ability to secure partnerships or further funding to advance its pipeline.
View full company profile